SOHO 2023 | Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial
Harry Erba
• 7 Sep 2023
Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the role of quizartinib in the treatment of patients with FLT3-ITD-mutated acute myeloid leukemia (AML), highlighting the results of the QuANTUM-First trial (NCT02668653). Dr Erba comments on the deeper responses and reduced risk of mortality observed with quizartinib compared to placebo, and recommends quizartinib as a frontline treatment in combination with intensive chemotherapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
